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JC virus causes the fatal demyelinating disease, progressive multifocal leukoencephalopathy (PML) under immunosuppressive states such
as AIDS. During the pathogenesis of AIDS, HIV-infected microglia secrete cytokines including interleukin-1 and tumor necrosis factor-a
(TNF-a), which affect neuronal cells resulting in dysfunction of the CNS. We hypothesized that extracellular stimuli released from HIV-
infected microglia may reactivate JC virus by affecting neighboring oligodendrocytes. In the present study, we found that phorbol myristate
acetate (PMA) and interleukin-1h (IL-1h) dramatically increased JC virus transcription in glial cells. Site-directed mutagenesis and gel shift
analyses revealed that PMA and IL-1h strongly induced nuclear factor-1 (NF-1) binding to the JC virus enhancer region, increasing
transcriptional activity of the viral early promoter. Additionally, we demonstrated that protein kinase C (PKC) pathways were involved in the
PMA/IL-1h-mediated up-regulation of the JC virus early promoter. These findings may represent one of the possible mechanisms for higher
incidence of PML among AIDS patients.
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Progressive multifocal leukoencephalopathy (PML) is a
fatal demyelinating disease that results from an oligoden-
drocyte infection caused by JC virus. JC virus selectively
destroys oligodendrocytes, leading to multiple areas of
demyelination and attendant loss of brain function (Astrom
et al., 1958; Zu Rhein and Chou, 1965). Although PML is
uncommon, JC virus is present in more than 80% of the
healthy human population (Major et al., 1992; Weber and
Major, 1997). On initial infection, JC virus establishes a
subclinical, persistent infection in the urinary tract or lym-
phoid tissues. Under immunosuppressive conditions includ-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.06.021
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snu.ac.kr (E.-C. Choi).ing lymphoproliferative diseases and AIDS, JC virus begins
to replicate in the brain, leading to PML (Berger and Concha,
1995; Seth et al., 2003). The above facts indicate that
immune system function may have an impact in reactivation
of viral gene expression and replication of JC virus.
The significantly higher incidence of PML in AIDS
patients compared to other immunosuppressive disorders
has suggested that the presence of HIV-1 in the brain may
participate, directly or indirectly, in the pathogenesis of this
disease. In support of this concept, previous studies have
demonstrated that the HIV-encoded transregulatory protein,
Tat, greatly increases the rate of transcription from the JC
virus late promoter (Chowdhury et al., 1992; Krachmarov et
al., 1996). In addition to its direct effect, Tat may stimulate
cytokine expression from HIV-infected microglia and thus
indirectly participate in deregulation of cellular genes and
activation of viral promoters in neural cells. On the other
hand, HIV-1 envelope protein gp120 has been reported to
stimulate microglia, astrocytes, or both to produce nitric
oxide and pro-inflammatory cytokines (Koka et al., 1995;
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factor-a (TNF-a), IL-1, and TGF-h, have been postulated to
contribute to the pathogenesis of the neurological complica-
tions of HIV-infection by acting on uninfected neighboring
cells or by stimulating the production of active viruses (HIV-
1, JCV, etc.) from persistently infected glial cells (Kaul et al.,
2001; Sweet et al., 2002). In support of this model, previous
reports have demonstrated that the late promoter of JC virus
was induced by PMA and TNF-a, which activated NF-nB
with subsequent increase of transcription (Mayreddy et al.,
1996; Ranganathan and Khalili, 1993; Safak et al., 1999a).
Other studies also showed that NF-nB motif responded to
extracellular stimuli such as TNF-a and interleukin-2, result-Fig. 1. Transcriptional activation of the MH1 JC virus early promoter by various
MH-1 JC virus early promoter. The promoter is fused to the firefly luciferase gen
represent TATA homologies, and striped boxes represent Sp1 binding sites upstrea
(black boxes) are also indicated. (B) Nucleotide sequence of JC virus promoter re
with pMH1long-luc plasmid DNA and treated with various cytokines, singly or in
1h (10 ng/ml), and PMA (100 ng/ml) for 24 h before harvesting cells. Luciferaseing in increased transcriptional activity of the viral late
promoter in glial cells (Mayreddy et al., 1996). Another
transcription factor, GBP-i (GGA/C binding protein) has
been reported to be induced by many inflammatory cytokines
including IL-1h, TNF-a, IFN-g, and TGF-h. GBP-i func-
tioned as a transcriptional repressor in the context of JC virus
late promoter (Raj and Khalili, 1994).
Thus, earlier studies on JC virus gene regulation by
cytokines have been mainly focused on the late promoter.
Moreover, the regulatory mechanisms have not been
clearly demonstrated. To better understand JC virus gene
regulation by exogenous activators including cytokines,
the present study investigated the effect of various cyto-cytokines and PMA. (A) Schematic of the reporter plasmid containing the
e. Open boxes indicate direct tandem repeats of the enhancer, dotted boxes
m of the TATA sequence. Binding sites for the viral protein large T antigen
gion in the MH1long-luc plasmid. (C) U87MG glial cells were transfected
combination: TNF-a (50 ng/ml), IFN-g (50 U/ml), TGF-h1 (10 ng/ml), IL-
assays were performed using cell extracts and relative activities are shown.
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promoter. Here, we report that PMA and IL-1h strongly
enhance transcriptional activity of the JC virus early
promoter in glial cells, and that the transcription factor
NF-1 plays a major role in this regulation.Results
PMA and IL-1b stimulate transcriptional activity of JC
virus early promoter in glial cells
A variety of cytokines have been reported to contribute
to CNS diseases by targeting neuronal and glial cells. To
investigate the effect of cytokines on JC virus early gene
expression, promoter activity was compared before and
after treatment with several cytokines (TNF-a, IFN-g, IL-
1h) or a cytokine-inducing agent such as PMA. As shown
in Fig. 1, treatment with PMA or IL-1h prominently
stimulated JC virus promoter activity about 4-fold. Con-
comitant treatment with PMA and IL-1h additively in-
creased the promoter activity. In contrast, TNF-a, TGF-
h1, or IFN-g had little effect on the promoter activity.
Similar results were observed with another JC virus early
promoter (i.e., Mad-1) and another glial cell line (i.e.,Fig. 2. Nuclear factor-1 binding sites in the enhancer region are important for PM
transfected with pMH1long-luc plasmid DNA carrying mutations, as shown on th
combination, for 24 h before harvesting cells. Luciferase assays were performed
mutant plasmid are presented in the graph and the fold inductions by PMA + I
dramatically decreased, whereas induction was not altered in other mutants, incluU373MG) (data not shown). These data suggest that
PMA and IL-1h specifically regulate the JC virus early
promoter in glial cells.
Nuclear factor-1 (NF-1) binding sites are critical for PMA/
IL-1b-induced activation
Next, we sought to identify transcription factors and
their cognate binding sites, which play an important role
in PMA/IL-1h-induced JC virus transcriptional activation.
Site-directed mutagenesis was performed in transcription
factor binding sites within the JC virus promoter/enhancer
region. Each mutant plasmid was transfected into U87MG
glial cells and the inducibility by treatment with PMA or
IL-1h, singly or in combination, was compared with that
of wild type. Interestingly, we found that mutation of NF-
1 sites in the enhancer region dramatically diminished
PMA/IL-1h-induced promoter activation (Fig. 2). Howev-
er, mutation of the NF-1 site in the distal region upstream
of enhancer did not produce any change in the fold
induction. Furthermore, mutation of AP1 sites in the
enhancer region or other transcription factor binding sites
in the proximal promoter region (e.g., pentanucleotide,
TATA, and Sp1 sites) did not significantly affect induc-
tion. Previous reports by other groups have suggested thatA/IL-1h-induced activation of JC virus early promoter. U87MG cells were
e left, and treated with IL-1h (10 ng/ml) or PMA (100 ng/ml), singly or in
using the cell extracts. Relative luciferase activities of wild type and each
L-1h are indicated on the right side. The induction of NF-1 mutants was
ding the distal NF-1 site (mNF-1-u).
S.-Y. Kim et al. / Virologythe NF-nB binding site is important for PMA-mediated
induction of JC virus late promoter. However, in our
experiments, mutation of the NF-nB site did not affect
PMA/IL-1h-mediated inducibility of early promoter. Thus,
our data indicate that NF-1 sites are important for PMA/
IL-1h-mediated activation of the JC virus early promoter.Fig. 3. Increase in NF-1 binding by PMA and IL-1h. (A) EMSA for NF-1 DNA
treatment with PMA + IL-1h for 1, 3, 6, and 12 h. Six micrograms of nuclear extrac
JC virus enhancer region and loaded onto each lane for gel mobility shift assay. Th
probe is shown on the right side of the panel. ‘‘S’’ in the parenthesis indicates se
DNA–protein complex indicated by the arrow was competed by cold NF-1
oligonucleotide, indicating that the complex is NF-1 sequence-specific. For compe
cold oligonucleotides were added to the reaction mixture containing 6 Ag of nuclea
radiolabeled probe. (C) Supershift assay with NF1-specific antibody. Nuclear extra
or 3 Ag of NF-1 antibody for 30 min before addition of P32-labeled probe. Coinc
diminished formation of a complex marked by the arrow. (D) Individual effect of P
nuclear extracts (6 Ag) from U87MG cells treated with PMA (100 ng/ml) or IL-1h
each lane for gel mobility shift assay. The result indicates that both PMA and ILTreatment with PMA and IL-1b prominently increase NF-1
binding to JC virus promoter
To determine whether PMA and IL-1h stimulate JC virus
promoter activity by enhancing NF-1 binding to the JC virus
promoter, electrophoretic mobility shift assay (EMSA) was
327 (2004) 60–69 63binding activity. Nuclear extracts were prepared from U87MG cells after
ts were incubated with a 32P-labeled probe containing NF-1 sequences from
e arrow indicates a DNA–protein complex of NF-1. The sequence of NF-1
nse strand and ‘‘A’’ indicates antisense strand. (B) Competition assay. The
or consensus NF-1 (cNF-1), but not by mutant NF-1 (mNF-1) or AP1
tition, 5-fold (lanes 2, 4, 6, 8) or 50-fold (lanes 3, 5, 7, 9) molar excesses of
r extracts isolated from PMA/IL-1h-treated U87MG cells before addition of
cts (6 Ag) from PMA/IL-1h-treated U87MG cells were pre-incubated with 1
ubation of nuclear extracts with NF-1 antibody but not with Sp1 antibody
MA and IL-1h on NF-1 binding. 32P-labeled NF-1 probe was incubated with
(10 ng/ml), individually, or in combination for 1, 3, 6, 12 h and loaded onto
-1h induce NF-1 binding.
Fig. 4. PMA induced AP1 binding to JC virus promoter without affecting
transcriptional activity. EMSA was performed using the same nuclear
extracts used in Fig. 3D. The nuclear extracts were incubated with
radiolabeled oligonucleotides containing the AP1 sequence on JC virus
enhancer. PMA, but not IL-1h, induced AP1 binding.
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binding sequences within the JC virus enhancer region were
incubated with nuclear extracts prepared from U87MG cells
treated with PMA and IL-1h in combination. As shown in
Fig. 3A, cotreatment of PMA and IL-1h dramatically
induced NF-1 binding at 1 h and the increased level
persisted at least up to 6 h. After that, the degree of binding
declined to basal level. The specificity of NF-1 protein–
DNA complexes was demonstrated by competition and
antibody supershift assays. Addition of unlabeled JCV
NF-1 or consensus NF-1 oligonucleotides reduced the
DNA–protein complex formation (Fig. 3B). In addition,
antibody supershift assay showed that pre-incubation of NF-
1-specific antibody with nuclear extract diminished the NF-
1-DNA binding (Fig. 3C). Because the antibody recognizes
the N-terminus of NF-1 protein, where DNA binding
domain resides, the complex of Ab-NF-1 may result in
masking of DNA binding domain, thus reducing the forma-
tion of NF-1–DNA complex without generating supershift
band as shown in Fig. 3C. These results suggest that PMA
and IL-1h may enhance JC virus transcription by increasing
the binding of NF-1 to enhancer region. We next examined
the individual role of PMA and IL-1h in NF-1 binding. Gel
shift assay showed that both PMA and IL-1h up-regulated
NF-1 binding and concomitant treatment of these two agents
additively increased NF-1 binding. NF-1 binding levels
decreased 6 h after treatment with PMA or IL-1h, alone
and in combination (Fig. 3D). Thus, PMA and IL-1h appear
to induce JC virus transcription by directly stimulating NF-1
binding to the promoter.
AP1 is not involved in PMA/IL-1b-mediated activation of
JC virus early promoter
Because PMA is generally known to induce AP1, we
compared AP1 binding after treatment with PMA and IL-
1h. We found that PMA, but not IL-1h, induced AP1
binding when the oligonucleotide containing the JC virus
AP1 site was used as a probe (Fig. 4). However, the increase
of AP1 binding was not accompanied by transcriptional
activation because mutation of AP1 sites did not affect
PMA-induced transactivation of JC virus promoter (Fig.
2). These data confirmed that NF-1 sites, but not AP1 sites,
play a critical role in PMA/IL-1h-induced transactivation.
On the other hand, the results raise the possibility that in the
full promoter context, AP1 binding may be blocked by NF-1
because their binding sites are adjacent or overlapped
(Amemiya et al., 1992). In support of this notion, when
the promoter region containing the two adjacent binding
sites was used as a probe, PMA and IL-1h induced only NF-
1, but not AP1 binding as demonstrated by competition and
antibody supershift assays (Figs. 5A–C).
Using nuclear extracts prepared at several time points,
EMSA revealed that PMA/IL-1h induced NF-1 binding as
early as 15 min, whereas AP1 binding was induced after 1
h in separate binding conditions (Fig. 5D). Thus, the resultscollectively suggest that prebinding of NF-1 induced by
PMA/IL-1h may interfere with AP1 binding at adjacent
sites on enhancer region.
PKCpathway appears to be involved in PMA/IL-1b-mediated
activation of JC virus early promoter
Because PMA is a strong inducer of protein kinase C, we
investigated whether PMA/IL-1h-induced transactivation
depends on protein kinase C (PKC) pathway. U87MG cells
were transfected with JC virus promoter and treated with a
specific PKC inhibitor (Ro-31-8220) before the addition of
PMA and IL-1h and gene expression was compared. As
shown in Fig. 6A, pretreatment with Ro-31-8220 signifi-
cantly suppressed PMA/IL-1h-induced transcriptional ac-
tivity in a dose-dependent manner. By treatment with 2 AM
Ro, the fold induction decreased to nearly basal levels. We
examined the effect of Ro on the fold induction by PMA
and IL-1h individually. Treatment of Ro (2 AM) efficiently
inhibited PMA- as well as IL-1h-induced transcriptional
activation. Finally, to determine the effect of Ro on PMA/
IL-1h-induced NF-1 promoter binding, EMSA was per-
formed. As shown in Fig. 6C, treatment of Ro efficiently
decreased NF-1 binding. The results indicate that the PKC
signaling pathway is involved in the induction of JC virus
early promoter by either PMA or IL-1h.Discussion
Although dozens of transcription factors have been
reported to regulate JC virus transcription, further upstream
events modulating JC virus transcription are not fully
Fig. 5. Prebinding of NF-1 may interfere with AP1 binding at adjacent binding sites on enhancer region. (A) EMSA using the probe containing both the NF-1
and AP1 sites as indicated. The same nuclear extracts used in Fig. 3A were incubated with radiolabeled probe. DNA–protein complex appeared at 1 h and
persisted up to 6 h. (B, C) Competition and supershift assay revealed that this DNA–protein complex contains NF-1, but not AP1. (D) Binding activity of NF-1
and AP1 at several time points (15, 30, 45, 60 min) after PMA/IL-1h stimulation. Nuclear extracts were prepared at indicated time points of induction and
EMSAwas performed using the probe containing NF-1 or AP1 sequence, respectively. Specific bands corresponding to NF-1 or AP1 complexes were scanned
by densitometer. Binding activity is represented in arbitrary units shown on the y-axis, and the time of PMA/IL-1h stimulation is shown on the x-axis.
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HIV-infected microglia may contribute to CNS dysfunction
(Garden, 2002; Kaul et al., 2001), extracellular stimuli
including cytokines could be crucial mediators that regulate
JC virus gene expression in glial cells.In the present study, we demonstrated that PMA and IL-
1h strongly enhanced JC virus early gene transcription and
that the transcription factor NF-1 plays an important role in
this induction. NF-1 is a well-known transcription factor
that regulates a variety of viral and endogenous inducible
Fig. 6. PKC inhibitor prominently repressed PMA/IL-1h-induced activation of JC virus early promoter. (A) U87MG cells were transfected with pMH1long-luc
and treated with various concentrations of the PKC inhibitor Ro-31-8220 for 1 h before stimulation with PMA (100 ng/ml) and IL-1h (10 ng/ml). After 24 h,
cells were harvested and the cell extracts were used for luciferase assay. Fold induction was decreased to almost basal level by 2 AM Ro. (B) The effect of Ro
on individual induction by PMA or IL-1h. After transfection of pMH1long-luc, U87MG cells were pretreated with 2 AM of Ro-31-8220 for 1 h, and then PMA
(100 ng/ml) or IL-1h (10 ng/ml) was added. After 24 h, the fold induction was assessed by luciferase assay. (C) The effect of Ro on PMA + IL-1h-induced NF-
1 binding (EMSA). U87MG cells were incubated with PMA + IL-1h in the absence or presence of Ro (2 AM) for 2 h and nuclear extracts were isolated. 32P-
labeled NF-1 probe and the above nuclear extracts were incubated, and the DNA–NF-1 protein complexes were resolved on the gel.
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genomes (Hebbar and Archer, 2003; Muller and Mermod,
2000). NF-1 binding sites also exist in the promoter/en-
hancer region of JC virus and may help to determine the
host range of JC virus infection. For example, the differen-
tiated progenitor cell line KG-1 became susceptible to JC
virus infection when the cells were transfected with an NF-1
class D expression plasmid (Monaco et al., 2001). In
addition, NF-1 appears to direct brain-specific expression
of JC virus by transactivating the JC virus early promoter by
a cerebellum-enriched form of NF1 (NF1-A1) (Krebs et al.,
1996). Furthermore, NF-1 sites have been reported to be
important for transactivation of the JC virus late promoter
by T antigen (Kumar et al., 1996). Thus, NF-1 is an essential
transcription factor regulating JC virus gene expression in
glial cells as well as JC virus-susceptible cells. In support of
this notion, our data strongly suggest a critical role of NF-1
in JC virus gene regulation by extracellular stimuli such as
PMA and IL-1h.
Because PMA is known to induce AP1, we tested the
possible involvement of AP1 in PMA and IL-1h-mediated
activation. EMSA and transient transfection assay indicated
that PMA-induced AP1 is not significantly responsible fortransactivation of JC virus by PMA or IL-1h. The present
study suggests that this could be due to interference of AP1
binding by prior occupancy of adjacent binding site by NF-1.
Electrophoretic mobility assay revealed that NF-1 bind-
ing was induced as early as 15 min and increased up to 3 h,
and then decreased over time. This result is compared with
the induction of GBP-i, which is a transcriptional repressor
that responds to cytokines and PMA. According to previous
reports, the expression of GBP-i was detected at 45 min and
increased up to 90 min and then decreased later (Raj and
Khalili, 1994). The results suggest that NF-1 is an earlier
responsive factor than GBP-i in the condition of extracellu-
lar stimuli such as cytokines and PMA. The immediate-early
class of signal transduction pathway is generally known to
involve posttranslational modification, often a protein ki-
nase-dependent phosphorylation step, and activation occurs
within 15 min (Crusius et al., 1997; Lanahan et al., 1992).
By Western blotting, we found that PMA/IL-1h did not
change the amount of NF-1 protein (data not shown). Thus,
the dependency of PMA/IL-1h-induced transactivation on
PKC pathway (Fig. 6) implies that posttranslational modi-
fication might be involved in early activation of NF1.
Considering the opposite function of two proteins in JC
S.-Y. Kim et al. / Virology 327 (2004) 60–69 67virus transcription (NF-1 increased JC virus early promoter
expression, while GBP-i repressed the late promoter), the
coordinated expression of these proteins may contribute to
regulation of early gene expression.
The transcription factor Pura interacts with Tat to acti-
vate the JC virus late promoter (Johnson, 2003; Krachmarov
et al., 1996). Pura may represent one of the possible
mechanisms for JC virus reactivation in the context of
HIV infection. However, to our knowledge, correlation
between Pura–Tat interaction and induced cytokine profiles
has not been reported. Considering that the binding site of
Pura–Tat complex (upTAR; upstream Tat response site)
overlaps with that of GBP-i, it may be plausible to speculate
that cytokines, GBP-i, or both may influence the Pura–Tat
interaction (Krachmarov et al., 1996; Raj and Khalili, 1994;
Safak et al., 1999b). Examination of possible interactions
among NF-1, GBP-i, Pura, and Tat would be an interesting
object of future study in terms of pathogenesis of PML.
Previous studies have showed that NF-nB plays an
important role in PMA and cytokine-induced JC virus
transcription, mainly through the late promoter (Mayreddy
et al., 1996; Ranganathan and Khalili, 1993). On the other
hand, our site-directed mutagenesis analysis revealed that
NF-nB did not have a significant role in early promoter
activation by PMA and IL-1h. Moreover, alteration of the
GBP-i site did not lessen the inducibility. Collectively, the
results suggest that these two factors (NF-nB, GBP-i) are
not involved in PMA/IL-1h-mediated activation of JC virus
early promoter, although they have a critical role in late
promoter activation.
In conclusion, the present study demonstrates that NF-1
plays an important role in PMA/IL-1h-mediated transacti-
vation of the JC virus early promoter. It suggests a possible
involvement of NF-1 in JC virus reactivation in immuno-
suppressive states such as AIDS.Materials and methods
Reagents
Phorbol myristate acetate (PMA) was purchased from
Sigma (St. Louis, MO). Interleukin-1h (IL-1h), TNF-a, and
TGF-h1 were purchased from Upstate Biotechnology (Lake
Placid, NY). IFN-g and the PKC-specific inhibitor, Ro-31-
8220, were obtained from Calbiochem (San Diego, CA).
Antibodies against NF-1, Sp1, and c-jun were purchased
from Santa Cruz biotechnology, Inc. (Santa Cruz, CA).
Cell culture and transient transfection assays
U87MG and U373MG human glioma cell lines were
grown in Dulbecco’s modified Eagle’s medium supple-
mented with 10% heat-inactivated fetal bovine serum
(Hyclone), streptomycin, and penicillin and maintained at
37 jC with 5% CO2. Transfection was performed by astandard calcium phosphate method. Cells (2  105 in 60-
mm-diameter dishes) were transfected with 4 Ag of the
reporter construct, 1 Ag of pRSV h-gal, and PUC19 plasmid
to a total of 10 Ag of DNA. Plasmids used for transient
transfection assays were prepared using Qiagen (Santa
Clarita, CA) columns. After 48 h, cells were harvested
and luciferase assays were performed as previously de-
scribed (Kim et al., 2003). To examine the effect of
cytokines, cells were treated with the following agents either
singly or in combination for 24 h before harvesting cells for
luciferase assays: PMA (100 ng/ml), IL-1h (10 ng/ml),
TNF-a (10 ng/ml), TGF-h1 (10 ng/ml), IFN-g (50 U/ml).
To determine whether PMA/IL-1h-induced activation is
dependent on the PKC pathway, cells were pretreated with
PKC-specific inhibitor, Ro-31-8220, 60 min before addition
of PMA/IL-1h. To correct for differences in transfection
efficiencies among different DNA precipitates, luciferase
activity was normalized to h-galactosidase activity deter-
mined by ONPG assay. Within cytokine treatment experi-
ments, luciferase values were normalized by protein
concentrations as determined by a protein assay reagent
from Bio-Rad. All transfection assays were performed at
least three times in duplicate.
Site-directed mutagenesis
The pMH1long-luc reporter construct contains the 408-
bp sequence upstream of the MH1-type JC virus large T
antigen gene fused to the firefly luciferase gene (Henson,
1994). Base substitutions in the promoter region of the JC
virus were generated in the context of the 408-bp upstream
sequence, using a QuickChange PCR-based site-directed
mutagenesis kit (Stratagene) according to the manufactur-
er’s procedure. The oligonucleotide sequences for generat-
ing mutants of pentanucleotide, TATA, and Sp1 sites are as
described previously (Henson et al., 1995; Kim et al., 2000).
For site-directed mutagenesis of NF-1 or AP1 binding sites
in the enhancer region, the following oligonucleotides were
used: 5V GAGCTCATGCTCTAACTCCAGCCATCCA 3V
and 5V CTGGATGGCTGGAGTTAGAG CATGAGCT 3V
for the NF-1 mutant, 5V CCTAGGTATGAGCTTG-
TGCTTGGCTGG 3Vand 5VGCCAGCCAAGCACAAGCT-
CATACCTAG 3Vfor the AP1 mutant. For mutation of NF-1
site on the distal region upstream of enhancer or NF-nB
binding site, the following oligonucleotides were used: 5V
CATGTTCCCTTTAAGTCTTTCCACTTCC 3V and 5V
GGGAAGTGGAAAGACTTAAAGGGAACAT 3V for the
upstream NF-1 mutant, 5V AGG AGGCCAGGTCCCG-
TCCCTTGTTTTTC 3V and 5V GGAAAAACAAGGGA-
CGGGACC TGGCCTCC 3V for the NF-nB mutant. The
first set of primers represents coding-strand sequences of
the promoter containing the desired mutations (underlined
bases), and the second set of primers represents the corres-
ponding noncoding-strand sequences. Constructs with de-
sired mutations were screened by restriction enzyme
digestion and sequencing analysis.
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Nuclear extracts were prepared from U87MG human
glioma cells as described by Dignam et al. (1983). After
treatment of cytokines as described above, cells were washed
twice with phosphate-buffered saline (PBS) and harvested by
scraping. The cells were disrupted with cold lysis buffer [10
mM Tris–HCl (pH 7.9), 10 mM NaCl, 3 mM MgCl2, 0.1%
NP-40] and the nuclei were pelleted by centrifugation at
13000 rpm and resuspended in extraction buffer [20 mM
HEPES (pH 7.9), 20% glycerol, 0.1 M KCl, 0.2 mM EDTA,
0.2 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothrei-
tol (DTT)] and dialyzed against the same buffer. The extracts
were quick-frozen in liquid N2 and aliquots were stored at
70 jC. Protein concentrations were determined by the
Bradford method. Sense and antisense oligonucleotides
encompassing the NF-1 or AP1 sites on the enhancer region
of JC virus promoter were synthesized. The sequences of the
oligomers are as follows: for NF-1, 5V GCTTGGCTGG-
CAGCCATCCAGTTT 3V (sense) and 5VAAAACTG GA-
TGGCTGCCAGCCAAG 3V (antisense), for AP1, 5V
TAGGTATGAGCTCATGCTTG 3V(sense) and 5VCCAAG-
CATGAGCTCATACCT 3V(antisense), and for NF-1 + AP1,
5VGTATGAGCTCATGCTTGGCTGGCAGCCATCCAG 3V
(sense) and 5V ACTGGATGGCT GCCAGCCAAGCAT-
GAGCTCATA 3V (antisense). The oligonucleotides were
annealed, labeled with [g-32P] ATP by using T4 polynucle-
otide kinase, and used as probes. The probes (50000 cpm)
were incubated with 6 Ag of nuclear extracts from U87MG
cells in a final volume of 20 Al of 12.5% glycerol, 12.5 mM
HEPES (pH 7.9), 4 mM Tris–HCl (pH 7.9), 60 mM KCl, 1
mM EDTA, and 1 mM DTT with 1 Ag of poly(dI-dC) as
described previously (Kim et al., 1998). The reaction
mixture was incubated at 4 jC for 30 min. For competition
binding assays, binding reaction reagents and nuclear
extracts were mixed with nonradioactive oligonucleotides
in molar excess and incubated before adding 32P-labeled
probe. For supershift assay, antibody was coincubated with
the nuclear extract mix for 30 min on ice before addition
of the radiolabeled probe. The binding products were
resolved on 5% polyacrylamide gel and visualized by
autoradiography.
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